Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 34-35

  Zampelas, Antonis ^a  

^a AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; METALLOPROTEINASE; OLEIC ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPID;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIETARY INTAKE; HUMAN; INFLAMMATION; LIPID COMPOSITION; MORBIDITY; MORTALITY; NOTE; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; CAPSULES; CAROTID ARTERY DISEASES; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; ENDARTERECTOMY, CAROTID; FOAM CELLS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASES; PHOSPHOLIPIDS; PREOPERATIVE CARE; RUPTURE, SPONTANEOUS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 77956228178     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.018     Document Type: Note

References (8)

1. Bang H.O., Dyerberg J., Nielsen A.B. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet 1971, 1(1):1143-1145.
2. Dyerberg J., Bang H.O., Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975, 28:958-966.
3. GISSI-HF Investigators Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
4. Roth E.M., Harris W.S. Fish oil for primary and secondary prevention of coronary heart disease. Curr Atheroscler Rep 2010, 12:66-72.
5. Mozzafarian D., Fish Mercury selenium and cardiovascular risk: current evidence and unanswered questions. Int J Environ Res Public Health 2009, 6:1894-1916.
6. Thies F., Garry J.M.C., Yaqoob P., et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet 2003, 361:477-485.
7. Geleijnse J.M., Giltay E.J., Schouten E.G., et al. Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline of the Alpha Omega Trial. Am Heart J 2010, 159:539-546.
8. The ORIGIN Trial Investigators Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN trial (Outcome Reduction with an Initial Clargine Intervention). Am Heart J 2008, 155:26-32.